ALGORAE PHARMACEUTICALS LIMITED — Director's Dealing 2020

Jul 7, 2020

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Living Cell Technologies Limited
ABN	14 104 028 042

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Ken Taylor
Date of last notice	6 December 2019

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest		Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.
Date of change		1 July 2020
No. of securities held prior to change		Unlisted options	Exercise Price	Expiry Date
		250,000	$0.100	01-Jul-20
		250,000	$0.100	01-Jul-21
		100,000	$0.140	01-Jul-20
		100,000	$0.190	01-Jul-21
		250,000	$0.0487	13-Dec-21
		Total 950,000
Class		Unlisted Options
Number acquired		Nil
Number disposed		350,000 unlisted options

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

==> picture [415 x 216] intentionally omitted <==

----- Start of picture text -----

Value/Consideration N/A
Note: If consideration is non-
cash, provide details and
estimated valuation
No. of securities held
after change Unlisted options Exercise Price Expiry Date
250,000 $0.100 01-Jul-21
100,000 $0.190 01-Jul-21
250,000 $0.0487 13-Dec-21
Total 600,000
Nature of change Lapse of unlisted options as detailed above.
Example: on-market trade, off-
market trade, exercise of
options, issue of securities
under dividend reinvestment
plan, participation in buy-back
----- End of picture text -----

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest
Name of registered holder (if issued securities)
Date of change
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change

Part 3 –[+] Closed period

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?
If prior written clearance was provided, on what date was this provided?

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3